Jude Y. Betow

Jude Y. Betow

Auto-generated profile, based on publicly available information

Jude Y. Betow

Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
JBJude Y Betow
Jude Y Betow
AQAmmar Qaseem
Ammar Qaseem
BBBoris Davy Bekono
Boris Davy Bekono
YFYue Feng
Yue Feng
AMAurélien F A Moumbock
Aurélien F A Moumbock
Fidele Ntie-KangFidele Ntie-Kang
Fidele Ntie-Kang
The African Natural Products Database (ANPDB) is a comprehensive repository currently encompassing over 11 000 natural compounds sourced from diverse species across the African continent. ANPDB integrates both experimental and predicted NMR and MS data to enhance compound annotation and facilitate dereplication, utilizing machine learning algorithms for spectral simulation and fragment prediction. The database offers a range of methods for compound structure search, including substructure matching, chemical similarity analysis, and property-based filtering, empowering users to efficiently explore chemical diversity. ANPDB also compiles detailed metadata on the traditional medicinal uses of source organisms, linking ethnobotanical knowledge with chemical and biological data. By consolidating information on biological sources, bioactivities, traditional applications, and bibliographic references (currently ranging from 1961 to 2024), ANPDB provides a robust platform for drug discovery, natural products research, and the exploration of Africa’s unique chemical and medicinal biodiversity. The database is open access, and the entire dataset and metadata are available for download and for computer-aided drug design endeavours. Link to the website: https://african-compounds.org

23 November 2024 in Molecular Informatics
Verified
Journal Article
Open access
JBJude Y. Betow
Jude Y. Betow
GTGemma Turon
Gemma Turon
CMClovis S. Metuge
Clovis S. Metuge
SASimeon Akame
Simeon Akame
SAShu Vanessa Asoh
Shu Vanessa Asoh
Fidele Ntie-KangFidele Ntie-Kang
Fidele Ntie-Kang
Diseases caused by viruses are challenging to contain, as their outbreak and spread could be very sudden, compounded by rapid mutations, making the development of drugs and vaccines a continued endeavour that requires fast discovery and preparedness. Targeting viral infections with small molecules remains one of the treatment options to reduce transmission and the disease burden. A lesson learned from the recent coronavirus disease (COVID‐19) is to collect ready‐to‐screen small molecule libraries in preparation for the next viral outbreak, and potentially find a clinical candidate before it becomes a pandemic. Public availability of diverse compound libraries, well annotated in terms of chemical structures and scaffolds, modes of action, and bioactivities are, therefore, crucial to ensure the participation of academic laboratories in these screening efforts, especially in resource‐limited settings where synthesis, testing and computing capacity are scarce. Here, we demonstrate a low‐resource approach to populate the chemical space of naturally occurring and synthetic small molecules that have shown in vitro and/or in vivo activities against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its target proteins. We have manually curated two datasets of small molecules (naturally occurring and synthetically derived) by reading and collecting (hand‐curating) the published literature. Information from the literature reveals that a majority of the reported SARS‐CoV‐2 compounds act by inhibiting the main protease, while 25% of the compounds currently have no known target. Scaffold analysis and principal component analysis revealed that the most common scaffolds in the datasets are quite distinct. We then expanded the initially manually curated dataset of over 1200 compounds via an ultra‐large scale 2D and 3D similarity search, obtaining an expanded collection of over 150 k purchasable compounds. The spanned chemical space significantly extends beyond that of a commercially available coronavirus library of more than 20 k small molecules and constitutes a good starting collection for virtual screening campaigns given its manageable size and proximity to hand‐curated compounds.

27 February 2026 in Scientific African
Verified
Journal Article
Open access
JOJoel Ojogbane Onoja
Joel Ojogbane Onoja
PMPirun Mikled
Pirun Mikled
JBJude Y. Betow
Jude Y. Betow
WCWarinthorn Chavasiri
Warinthorn Chavasiri

28 October 2025 in Scientific African
Verified
Journal Article
Open access
LALoveline N. Amen
Loveline N. Amen
JBJude Y. Betow
Jude Y. Betow
MTMathieu J.M. Tjegbe
Mathieu J.M. Tjegbe
GNGotoum Nadjinangar
Gotoum Nadjinangar
JWJean Duplex Wansi
Jean Duplex Wansi
Fidele Ntie-KangFidele Ntie-Kang
Fidele Ntie-Kang

24 August 2026 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
Fidele Ntie-KangFidele Ntie-Kang
Fidele Ntie-Kang
JBJude Y. Betow
Jude Y. Betow
DEDonatus Bekindaka Eni
Donatus Bekindaka Eni
JMJonathan A. Metuge
Jonathan A. Metuge
AAAlbisto Adriano
Albisto Adriano
Jutta Ludwig-MüllerJutta Ludwig-Müller
Jutta Ludwig-Müller
The Computational Applications in Secondary Metabolite Discovery (CAiSMD) 2026 workshop was held from 24 to 26 March 2026 in a hybrid format, combining ons

21 October 2026 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
MTMathieu J. M. Tjegbe
Mathieu J. M. Tjegbe
POPascal Amoa Onguéné
Pascal Amoa Onguéné
BBBoris Davy Bekono
Boris Davy Bekono
JBJude Y. Betow
Jude Y. Betow
Conrad Simoben VeransoConrad Simoben Veranso
Conrad Simoben Veranso
ITIan Tietjen
Ian Tietjen
Natural product (NP)-based chemical libraries are a rich source of antiviral compounds that can serve as the basis for new therapeutic leads to treat viral diseases, particularly for individuals lacking sustained access to existing vaccines and therapeutics. To identify new NP-based candidate inhibitors of SARS-CoV-2 cellular entry and viral replication, we screened the pan-African Natural Products Library (p-ANAPL), a collection of physical pure compounds obtained from African medicinal plants, for NPs that can disrupt the in vitro interaction of the SARS-CoV-2 Spike receptor-binding domain (RBD) with its host ACE2 entry receptor. This screen identified three compounds – oleanolic acid, poinsettifolin B, and rhuschalcone III – which disrupt RBD/ACE2 interactions with half-maximal inhibitory concentrations (IC 50 s) of 0.5–2.4 µM but do not disrupt an unrelated PD-1/PD-L1 host ligand/receptor binding pair. Oleanolic acid and rhuschalcone III, but not poinsettifolin B, additionally inhibited SARS-CoV-2 replication in Vero cells without cytotoxicity at low micromolar concentrations. Computational modelling indicated that all three compounds interact with numerous RBD and ACE2 residues, including a subset conserved across SARS-CoV-2 variants of concern. Taken together, we identify three NPs that selectively interfere with factors involved in SARS-CoV-2 entry and/or viral replication, representing new antiviral leads for COVID-19 management in resource-limited areas.